These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 32147920)
1. The inferiority of noninferiority trials. Udayasiri DK; Skandarajah A; Hayes IP ANZ J Surg; 2020 Mar; 90(3):203-205. PubMed ID: 32147920 [No Abstract] [Full Text] [Related]
2. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. Angeli F; Verdecchia P; Reboldi G Am J Cardiovasc Drugs; 2020 Jun; 20(3):229-238. PubMed ID: 31650521 [TBL] [Abstract][Full Text] [Related]
3. [Non-inferiority and equivalence trials: Key methodological issues]. Herr M; Descatha A; Aegerter P Rev Med Interne; 2018 May; 39(5):352-359. PubMed ID: 28693836 [TBL] [Abstract][Full Text] [Related]
4. Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. Aupiais C; Zohar S; Taverny G; Le Roux E; Boulkedid R; Alberti C Arch Dis Child; 2018 Nov; 103(11):1067-1075. PubMed ID: 29794107 [TBL] [Abstract][Full Text] [Related]
5. Equivalence And Non-Inferiority Trials In A Snapshot. Kerai S J Ayub Med Coll Abbottabad; 2017; 29(3):371-372. PubMed ID: 29076663 [No Abstract] [Full Text] [Related]
6. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials. Aberegg SK; Hersh AM; Samore MH J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400 [TBL] [Abstract][Full Text] [Related]
7. Noninferiority drug trials fail to report adequate methodological detail: an assessment of noninferiority trials from 2010 to 2015. Hong J; Tung A; Kinkade A; Tejani AM J Clin Epidemiol; 2019 Apr; 108():144-146. PubMed ID: 30529004 [No Abstract] [Full Text] [Related]
8. Methodological quality of oncology noninferiority clinical trials. Wayant C; Ross A; Vassar M Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223 [TBL] [Abstract][Full Text] [Related]
15. Assessing noninferiority: Evaluating efficacy of a new treatment without complete data. Gao P; Odem-Davis K Pharm Stat; 2019 Oct; 18(5):546-554. PubMed ID: 30977258 [TBL] [Abstract][Full Text] [Related]
16. Most noninferiority trials were not designed to preserve active comparator treatment effects. Tsui M; Rehal S; Jairath V; Kahan BC J Clin Epidemiol; 2019 Jun; 110():82-89. PubMed ID: 30858020 [TBL] [Abstract][Full Text] [Related]